Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 5/2017

27.04.2017 | Original Article

A novel conditional Sgsh knockout mouse model recapitulates phenotypic and neuropathic deficits of Sanfilippo syndrome

verfasst von: Adeline A. Lau, Barbara M. King, Carly L. Thorsen, Sofia Hassiotis, Helen Beard, Paul J. Trim, Lauren S. Whyte, Sarah J. Tamang, Stephen K. Duplock, Marten F. Snel, John J. Hopwood, Kim M. Hemsley

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Mucopolysaccharidosis (MPS) type IIIA, or Sanfilippo syndrome, is a neurodegenerative lysosomal storage disorder caused by a deficiency of the lysosomal enzyme N-sulfoglucosamine sulfohydrolase (SGSH), involved in the catabolism of heparan sulfate. The clinical spectrum is broad and the age of symptom onset and the degree of preservation of cognitive and motor functions appears greatly influenced by genotype. To explore this further, we generated a conditional knockout (Sgsh KO ) mouse model with ubiquitous Sgsh deletion, and compared the clinical and pathological phenotype with that of the spontaneous Sgsh D31N MPS-IIIA mouse model. Phenotypic deficits were noted in Sgsh KO mice prior to Sgsh D31N mice, however these outcomes did not correlate with any shift in the time of appearance nor rate of accumulation of primary (heparan sulfate) or secondary substrates (GM2/GM3 gangliosides). Other disease lesions (elevations in lysosomal integral membrane protein-II expression, reactive astrocytosis and appearance of ubiquitin-positive inclusions) were also comparable between affected mouse strains. This suggests that gross substrate storage and these neuropathological markers are neither primary determinants, nor good biomarkers/indicators of symptom generation, confirming similar observations made recently in MPS-IIIA patients. The Sgsh KO mouse will be a useful tool for elucidation of the neurological basis of disease and assessment of the clinical efficacy of new treatments for Sanfilippo syndrome.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Arfi A, Richard M, Gandolphe C, Bonnefont-Rousselot D, Therond P, Scherman D (2011) Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment. Mol Genet Metab 103:18–25CrossRefPubMed Arfi A, Richard M, Gandolphe C, Bonnefont-Rousselot D, Therond P, Scherman D (2011) Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment. Mol Genet Metab 103:18–25CrossRefPubMed
Zurück zum Zitat Bhaumik M, Muller VJ, Rozaklis T et al (1999) A mouse model for mucopolysaccharidosis type III a (Sanfilippo syndrome). Glycobiology 9:1389–1396CrossRefPubMed Bhaumik M, Muller VJ, Rozaklis T et al (1999) A mouse model for mucopolysaccharidosis type III a (Sanfilippo syndrome). Glycobiology 9:1389–1396CrossRefPubMed
Zurück zum Zitat Crawley AC, Gliddon BL, Auclair D et al (2006) Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA. Brain Res 1104:1–17CrossRefPubMed Crawley AC, Gliddon BL, Auclair D et al (2006) Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA. Brain Res 1104:1–17CrossRefPubMed
Zurück zum Zitat Elrick MJ, Pacheco CD, Yu T et al (2010) Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration. Hum Mol Genet 19:837–847CrossRefPubMed Elrick MJ, Pacheco CD, Yu T et al (2010) Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration. Hum Mol Genet 19:837–847CrossRefPubMed
Zurück zum Zitat Fraldi A, Hemsley K, Crawley A et al (2007) Functional correction of CNS lesions in a MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Hum Mol Genet 16:2693–2702CrossRefPubMed Fraldi A, Hemsley K, Crawley A et al (2007) Functional correction of CNS lesions in a MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Hum Mol Genet 16:2693–2702CrossRefPubMed
Zurück zum Zitat Giulian D, Woodward J, Young DG, Krebs JF, Lachman LB (1988) Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization. J Neurosci 8:2485–2490PubMed Giulian D, Woodward J, Young DG, Krebs JF, Lachman LB (1988) Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization. J Neurosci 8:2485–2490PubMed
Zurück zum Zitat Griffey MA, Wozniak D, Wong M et al (2006) CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Mol Ther 13:538–547CrossRefPubMed Griffey MA, Wozniak D, Wong M et al (2006) CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Mol Ther 13:538–547CrossRefPubMed
Zurück zum Zitat Haurigot V, Marco S, Ribera A et al (2013) Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest 123:3254–3271CrossRefPubMedCentral Haurigot V, Marco S, Ribera A et al (2013) Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest 123:3254–3271CrossRefPubMedCentral
Zurück zum Zitat Hemsley KM, Beard H, King BM, Hopwood JJ (2008) Effect of high dose, repeated intra-CSF injection of sulphamidase on neuropathology in MPS IIIA mice. Genes Brain Behav 7:740–753CrossRef Hemsley KM, Beard H, King BM, Hopwood JJ (2008) Effect of high dose, repeated intra-CSF injection of sulphamidase on neuropathology in MPS IIIA mice. Genes Brain Behav 7:740–753CrossRef
Zurück zum Zitat Hemsley KM, Hopwood JJ (2005) Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA). Behav Brain Res 158:191–199CrossRefPubMed Hemsley KM, Hopwood JJ (2005) Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA). Behav Brain Res 158:191–199CrossRefPubMed
Zurück zum Zitat Hemsley KM, Luck AJ, Crawley AC et al (2009) Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease. Eur J Neurosci 29:1197–1214CrossRefPubMed Hemsley KM, Luck AJ, Crawley AC et al (2009) Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease. Eur J Neurosci 29:1197–1214CrossRefPubMed
Zurück zum Zitat Hopwood JJ, Elliott H (1982) Diagnosis of Sanfilippo a syndrome by estimation of sulphamidase activity using a radiolabelled tetrasaccharide substrate. Clin Chim Acta 123:241–250CrossRefPubMed Hopwood JJ, Elliott H (1982) Diagnosis of Sanfilippo a syndrome by estimation of sulphamidase activity using a radiolabelled tetrasaccharide substrate. Clin Chim Acta 123:241–250CrossRefPubMed
Zurück zum Zitat Keating DJ, Winter MA, Hemsley KM et al (2012) Exocytosis is impaired in mucopolysaccharidosis IIIA mouse chromaffin cells. Neuroscience 227:110–118CrossRefPubMed Keating DJ, Winter MA, Hemsley KM et al (2012) Exocytosis is impaired in mucopolysaccharidosis IIIA mouse chromaffin cells. Neuroscience 227:110–118CrossRefPubMed
Zurück zum Zitat Lau AA, Crawley AC, Hopwood JJ, Hemsley KM (2008) Open field locomotor activity and anxiety-related behaviors in mucopolysaccharidosis type IIIA mice. Behav Brain Res 91:130–136CrossRef Lau AA, Crawley AC, Hopwood JJ, Hemsley KM (2008) Open field locomotor activity and anxiety-related behaviors in mucopolysaccharidosis type IIIA mice. Behav Brain Res 91:130–136CrossRef
Zurück zum Zitat Lau AA, Hopwood JJ, Kremer EJ, Hemsley KM (2010) SGSH gene transfer in mucopolysaccharidosis type IIIA mice using canine adenovirus vectors. Mol Genet Metab 100:168–175CrossRefPubMed Lau AA, Hopwood JJ, Kremer EJ, Hemsley KM (2010) SGSH gene transfer in mucopolysaccharidosis type IIIA mice using canine adenovirus vectors. Mol Genet Metab 100:168–175CrossRefPubMed
Zurück zum Zitat Lau AA, Shamsani NJ, Winner LK et al (2013) Neonatal bone marrow transplantation in MPS IIIA mice. JIMD reports 8:121–132CrossRefPubMed Lau AA, Shamsani NJ, Winner LK et al (2013) Neonatal bone marrow transplantation in MPS IIIA mice. JIMD reports 8:121–132CrossRefPubMed
Zurück zum Zitat Marco S, Pujol A, Roca C, et al (2016) Progressive neurologic and somatic disease in a novel model of human mucopolysaccharidosis type IIIC. Dis Model Mech doi:10.1242/dmm.025171 Marco S, Pujol A, Roca C, et al (2016) Progressive neurologic and somatic disease in a novel model of human mucopolysaccharidosis type IIIC. Dis Model Mech doi:10.1242/dmm.025171
Zurück zum Zitat Marshall NR, Hassiotis S, King B et al (2015) Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods. Exp Neurol 263:79–90CrossRefPubMed Marshall NR, Hassiotis S, King B et al (2015) Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods. Exp Neurol 263:79–90CrossRefPubMed
Zurück zum Zitat Martins C, Hulkova H, Dridi L et al (2015) Neuroinflammation, mitochondrial defects and neurodegeneration in mucopolysaccharidosis III type C mouse model. Brain 138:336–355CrossRefPubMedPubMedCentral Martins C, Hulkova H, Dridi L et al (2015) Neuroinflammation, mitochondrial defects and neurodegeneration in mucopolysaccharidosis III type C mouse model. Brain 138:336–355CrossRefPubMedPubMedCentral
Zurück zum Zitat Matern D, Gavrilov D, Oglesbee D, Raymond K, Rinaldo P, Tortorelli S (2015) Newborn screening for lysosomal storage disorders. Semin Perinatol 39:206–216CrossRefPubMed Matern D, Gavrilov D, Oglesbee D, Raymond K, Rinaldo P, Tortorelli S (2015) Newborn screening for lysosomal storage disorders. Semin Perinatol 39:206–216CrossRefPubMed
Zurück zum Zitat Russell C (2003) Transgenic expression of human alpha-L-iduronidase in mouse and characterization of the long term pathophysiology of murine alpha-L-iduronidase deficiency. In: Transgenic expression of human alpha-L-iduronidase in mouse and characterization of the long term pathophysiology of murine alpha-L-iduronidase deficiency. University of British Colombia, p 177 Russell C (2003) Transgenic expression of human alpha-L-iduronidase in mouse and characterization of the long term pathophysiology of murine alpha-L-iduronidase deficiency. In: Transgenic expression of human alpha-L-iduronidase in mouse and characterization of the long term pathophysiology of murine alpha-L-iduronidase deficiency. University of British Colombia, p 177
Zurück zum Zitat Savas PS, Hemsley KM, Hopwood JJ (2004) Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA. Mol Genet Metab 82:273–285CrossRefPubMed Savas PS, Hemsley KM, Hopwood JJ (2004) Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA. Mol Genet Metab 82:273–285CrossRefPubMed
Zurück zum Zitat Sergijenko A, Langford-Smith A, Liao AY et al (2013) Myeloid/microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease. Mol Ther 21:1938–1949CrossRefPubMedPubMedCentral Sergijenko A, Langford-Smith A, Liao AY et al (2013) Myeloid/microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease. Mol Ther 21:1938–1949CrossRefPubMedPubMedCentral
Zurück zum Zitat Shapiro EG, Nestrasil I, Delaney KA et al (2016) A prospective natural history study of mucopolysaccharidosis type IIIA. J Pediatr 170(278–287):e274 Shapiro EG, Nestrasil I, Delaney KA et al (2016) A prospective natural history study of mucopolysaccharidosis type IIIA. J Pediatr 170(278–287):e274
Zurück zum Zitat Sorrentino NC, D’Orsi L, Sambri I et al (2013) A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA. EMBO molecular medicine 5:675–690CrossRefPubMedPubMedCentral Sorrentino NC, D’Orsi L, Sambri I et al (2013) A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA. EMBO molecular medicine 5:675–690CrossRefPubMedPubMedCentral
Zurück zum Zitat Trim PJ, Hopwood JJ, Snel MF (2015) Butanolysis derivatization: improved sensitivity in LC-MS/MS quantitation of heparan sulfate in urine from Mucopolysaccharidosis patients. Anal Chem 87:9243–9250CrossRefPubMed Trim PJ, Hopwood JJ, Snel MF (2015) Butanolysis derivatization: improved sensitivity in LC-MS/MS quantitation of heparan sulfate in urine from Mucopolysaccharidosis patients. Anal Chem 87:9243–9250CrossRefPubMed
Zurück zum Zitat Valstar MJ, Marchal JP, Grootenhuis M, Colland V, Wijburg FA (2011) Cognitive development in patients with mucopolysaccharidosis type III (Sanfilippo syndrome). Orphanet journal of rare diseases 6:43CrossRefPubMedPubMedCentral Valstar MJ, Marchal JP, Grootenhuis M, Colland V, Wijburg FA (2011) Cognitive development in patients with mucopolysaccharidosis type III (Sanfilippo syndrome). Orphanet journal of rare diseases 6:43CrossRefPubMedPubMedCentral
Zurück zum Zitat Valstar MJ, Neijs S, Bruggenwirth HT et al (2010) Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann Neurol 68:876–887CrossRefPubMed Valstar MJ, Neijs S, Bruggenwirth HT et al (2010) Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann Neurol 68:876–887CrossRefPubMed
Zurück zum Zitat Valstar MJ, Ruijter GJ, van Diggelen OP, Poorthuis BJ, Wijburg FA (2008) Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 31:240–252CrossRefPubMed Valstar MJ, Ruijter GJ, van Diggelen OP, Poorthuis BJ, Wijburg FA (2008) Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 31:240–252CrossRefPubMed
Zurück zum Zitat Van Hove JL, Wevers RA, Van Cleemput J et al (2003) Late-onset visceral presentation with cardiomyopathy and without neurological symptoms of adult Sanfilippo a syndrome. Am J Med Genet A 118:382–387CrossRef Van Hove JL, Wevers RA, Van Cleemput J et al (2003) Late-onset visceral presentation with cardiomyopathy and without neurological symptoms of adult Sanfilippo a syndrome. Am J Med Genet A 118:382–387CrossRef
Zurück zum Zitat Villani GR, Gargiulo N, Faraonio R, Castaldo S, Gonzalez YRE, Di Natale P (2007) Cytokines, neurotrophins, and oxidative stress in brain disease from mucopolysaccharidosis IIIB. J Neurosci Res 85:612–622CrossRefPubMed Villani GR, Gargiulo N, Faraonio R, Castaldo S, Gonzalez YRE, Di Natale P (2007) Cytokines, neurotrophins, and oxidative stress in brain disease from mucopolysaccharidosis IIIB. J Neurosci Res 85:612–622CrossRefPubMed
Zurück zum Zitat Vitry S, Ausseil J, Hocquemiller M, Bigou S, Dos Santos CR, Heard JM (2009) Enhanced degradation of synaptophysin by the proteasome in mucopolysaccharidosis type IIIB. Mol Cell Neurosci 41:8–18CrossRefPubMed Vitry S, Ausseil J, Hocquemiller M, Bigou S, Dos Santos CR, Heard JM (2009) Enhanced degradation of synaptophysin by the proteasome in mucopolysaccharidosis type IIIB. Mol Cell Neurosci 41:8–18CrossRefPubMed
Zurück zum Zitat Whyte L, Hopwood J, Hemsley K, Lau A (2015) Variables influencing fluorimetric N-sulfoglucosamine sulfohydrolase (SGSH) activity measurement in brain homogenates. Molecular Genetics and Metabolism Reports 5:60–62CrossRefPubMedPubMedCentral Whyte L, Hopwood J, Hemsley K, Lau A (2015) Variables influencing fluorimetric N-sulfoglucosamine sulfohydrolase (SGSH) activity measurement in brain homogenates. Molecular Genetics and Metabolism Reports 5:60–62CrossRefPubMedPubMedCentral
Zurück zum Zitat Wilkinson FL, Holley RJ, Langford-Smith KJ et al (2012) Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB. PLoS One 7:e35787CrossRefPubMedPubMedCentral Wilkinson FL, Holley RJ, Langford-Smith KJ et al (2012) Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB. PLoS One 7:e35787CrossRefPubMedPubMedCentral
Metadaten
Titel
A novel conditional Sgsh knockout mouse model recapitulates phenotypic and neuropathic deficits of Sanfilippo syndrome
verfasst von
Adeline A. Lau
Barbara M. King
Carly L. Thorsen
Sofia Hassiotis
Helen Beard
Paul J. Trim
Lauren S. Whyte
Sarah J. Tamang
Stephen K. Duplock
Marten F. Snel
John J. Hopwood
Kim M. Hemsley
Publikationsdatum
27.04.2017
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe 5/2017
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-017-0044-4

Weitere Artikel der Ausgabe 5/2017

Journal of Inherited Metabolic Disease 5/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.